VIVANI MEDICAL, INC. (VANI) Reports the reporting period Financial Results
VIVANI MEDICAL, INC. (VANI) announced its financial results for the period ending the reporting period.
Key Financial Highlights:
Revenue: Not disclosed
Net Income: Not disclosed
EPS: Not disclosed
Cash and equivalents: 16232
139, a novel semaglutide implant, based on promising results from the LIBERATE
1 clinical study and additional positive data from a preclinical study with a semaglutide implant. LIBERATE
human application of Vivani’s proprietary NanoPortal implant technology, demonstrated a positive safety and tolerability profile and encouraging performance data. Vivani also announced new NPM
📋 VIVANI MEDICAL, INC. (VANI) - Financial Results
Filing Date: 2026-03-26
Accepted: 2026-03-26 16:36:39
Event Type: Financial Results
Event Details:
📊 Key Financial Metrics (Year-over-Year Comparison):
💼 Business Developments:
Structured Data: